15 Aug, 2018 RNAi Roundtable: Lumasiran, in Development for the Treatment of Primary Hyperoxaluria Type 1
On August 15, 2018, we hosted an online RNAi Roundtable to review the progress with lumasiran, an RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1.
- Pritesh Gandhi, Pharm.D., Vice President, General Manager, Lumasiran
- Richard Riese, M.D., Ph.D., Vice President, Clinical Development
- Sally-Anne Hulton, M.D., FRCPCH, MRCP, FCP, MBBCh, Consultant Paediatric Nephrologist and Clinical Lead, Birmingham Children’s Hospital NHS Trust
- Kim Hollander, Executive Director, Oxalosis & Hyperoxaluria Foundation